Patents Assigned to MABLINK BIOSCIENCE
  • Antibody drug conjugate (ADC) targeting Nectin 4 and comprising an exatecan payload
    Patent number: 12419964
    Abstract: The present disclosure provides Nectin-4 antibody drug conjugates (ADCs) comprising exatecan and pharmaceutical compositions thereof, and methods of using the ADCs for the treatment of cancer.
    Type: Grant
    Filed: October 2, 2024
    Date of Patent: September 23, 2025
    Assignees: ELI LILLY AND COMPANY, UNIVERSITÉ D'AIX-MARSEILLE, INSERM (Institut National De La Sante Et De La Recherche Medicale), INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS, MABLINK BIOSCIENCE, UNIVERSITE CLAUDE BERNARD LYON
    Inventors: Jacobus Petrus Maria Elands, Joanna Fares, Guy Fournet, Benoit Joseph, Florence Lhospice, Marc Lopez, Daniel Olive, Xavier Preville, Warren Viricel
  • ENZYME-TRIGGERED SELF-REACTING LINKER HAVING IMPROVED PHYSICOCHEMICAL AND PHARMACOLOGICAL PROPERTIES
    Publication number: 20240216525
    Abstract: Enzyme-triggered self-reacting arm compounds and chemical intermediates used for preparing such compounds and uses thereof, specifically in prodrug design and conjugation technologies. A Ligand-Drug-Conjugate (LDC) includes such enzyme-triggered self-reacting arms.
    Type: Application
    Filed: March 30, 2022
    Publication date: July 4, 2024
    Applicants: MABLINK BIOSCIENCE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS -, UNIVERSITE CLAUDE BERNARD LYON 1
    Inventors: Warren VIRICEL, Benoît JOSEPH, Guy FOURNET
  • LIGAND-DRUG-CONJUGATE COMPRISING A SINGLE MOLECULAR WEIGHT POLYSARCOSINE
    Publication number: 20200345863
    Abstract: A Ligand-Drug-Conjugate (LDC) including a single molecular weight homopolymer, in particular a single molecular weight polysarcosine.
    Type: Application
    Filed: October 23, 2018
    Publication date: November 5, 2020
    Applicant: MABLINK BIOSCIENCE
    Inventor: Warren VIRICEL